EP Patent

EP3317264B1 — Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone

Assigned to Exelixis Inc · Expires 2025-09-10 · 1y expired

What this patent protects

Patent listed against cobimetinib-fumarate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3317264B1
Jurisdiction
EP
Classification
—
Expires
2025-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.